Galectin Therapeutics | GALT - Net Income

Stock Price
3.02
Daily Change
0.05 1.68%
Monthly
-3.21%
Yearly
106.85%
Q1 Forecast
2.88

Galectin Therapeutics reported $-12.37M in Net Income for its fiscal quarter ending in June of 2024.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Galectin Therapeutics USD -12.37M 880K Jun/2024
Gilead Sciences USD 2.18B 869M Dec/2025
Immunic USD -24.37M 2.99M Sep/2024
Incyte USD 299.28M 124.89M Dec/2025
Merck USD 2.96B 2.82B Dec/2025